These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37017910)

  • 21. Prodromal dementia with Lewy bodies.
    Fujishiro H; Nakamura S; Sato K; Iseki E
    Geriatr Gerontol Int; 2015 Jul; 15(7):817-26. PubMed ID: 25690399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome Measures for Dementia With Lewy Body Clinical Trials: A Review.
    Patel B; Irwin DJ; Kaufer D; Boeve BF; Taylor A; Armstrong MJ
    Alzheimer Dis Assoc Disord; 2022 Jan-Mar 01; 36(1):64-72. PubMed ID: 34393189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prodromal Dementia with Lewy Bodies: A Case Series of the 3 Prodromal Types from Clinical Practice.
    Tholanikunnel T; Chapin B; Armstrong M
    Case Rep Neurol; 2023; 15(1):199-206. PubMed ID: 37933327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort.
    Blanc F; Bouteloup V; Paquet C; Chupin M; Pasquier F; Gabelle A; Ceccaldi M; de Sousa PL; Krolak-Salmon P; David R; Fischer C; Dartigues JF; Wallon D; Moreaud O; Sauvée M; Belin C; Harston S; Botzung A; Albasser T; Demuynck C; Namer I; Habert MO; Kremer S; Bousiges O; Verny M; Muller C; Philippi N; Chene G; Cretin B; Mangin JF; Dufouil C
    Alzheimers Res Ther; 2022 Jul; 14(1):96. PubMed ID: 35854388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prodromal Dementia With Lewy Bodies: Evolution of Symptoms and Predictors of Dementia Onset.
    Wyman-Chick KA; O'Keefe LR; Weintraub D; Armstrong MJ; Rosenbloom M; Martin PK; Barclay TR; Barrett MJ
    J Geriatr Psychiatry Neurol; 2022 Jul; 35(4):527-534. PubMed ID: 34114509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's disease drug development pipeline: 2017.
    Cummings J; Lee G; Mortsdorf T; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2017 Sep; 3(3):367-384. PubMed ID: 29067343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological Management of Dementia with Lewy Bodies.
    Hershey LA; Coleman-Jackson R
    Drugs Aging; 2019 Apr; 36(4):309-319. PubMed ID: 30680679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies.
    McKeith IG; Perry EK; Perry RH
    Neurology; 1999 Sep; 53(5):902-5. PubMed ID: 10496243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.
    McFarthing K; Rafaloff G; Baptista M; Mursaleen L; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2022; 12(4):1073-1082. PubMed ID: 35527571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain perfusion in dementia with Lewy bodies and Alzheimer's disease: an arterial spin labeling MRI study on prodromal and mild dementia stages.
    Roquet D; Sourty M; Botzung A; Armspach JP; Blanc F
    Alzheimers Res Ther; 2016 Jul; 8():29. PubMed ID: 27401267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies.
    McCleery J; Morgan S; Bradley KM; Noel-Storr AH; Ansorge O; Hyde C
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010633. PubMed ID: 25632881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage.
    Bousiges O; Philippi N; Lavaux T; Perret-Liaudet A; Lachmann I; Schaeffer-Agalède C; Anthony P; Botzung A; Rauch L; Jung B; de Sousa PL; Demuynck C; Martin-Hunyadi C; Cretin B; Blanc F
    Alzheimers Res Ther; 2020 Sep; 12(1):120. PubMed ID: 32993772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.
    McKeith IG; Boeve BF; Dickson DW; Halliday G; Taylor JP; Weintraub D; Aarsland D; Galvin J; Attems J; Ballard CG; Bayston A; Beach TG; Blanc F; Bohnen N; Bonanni L; Bras J; Brundin P; Burn D; Chen-Plotkin A; Duda JE; El-Agnaf O; Feldman H; Ferman TJ; Ffytche D; Fujishiro H; Galasko D; Goldman JG; Gomperts SN; Graff-Radford NR; Honig LS; Iranzo A; Kantarci K; Kaufer D; Kukull W; Lee VMY; Leverenz JB; Lewis S; Lippa C; Lunde A; Masellis M; Masliah E; McLean P; Mollenhauer B; Montine TJ; Moreno E; Mori E; Murray M; O'Brien JT; Orimo S; Postuma RB; Ramaswamy S; Ross OA; Salmon DP; Singleton A; Taylor A; Thomas A; Tiraboschi P; Toledo JB; Trojanowski JQ; Tsuang D; Walker Z; Yamada M; Kosaka K
    Neurology; 2017 Jul; 89(1):88-100. PubMed ID: 28592453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The ANeED study - ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial.
    Chwiszczuk LJ; Breitve MH; Kirsebom BB; Selnes P; Fløvig JC; Knapskog AB; Skogseth RE; Hubbers J; Holst-Larsen E; Rongve A
    Front Aging Neurosci; 2023; 15():1163184. PubMed ID: 37304077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review.
    Tahami Monfared AA; Meier G; Perry R; Joe D
    Neurol Ther; 2019 Dec; 8(2):289-305. PubMed ID: 31512165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protocol for an observational cohort study identifying factors predicting accurately end of life in dementia with Lewy bodies and promoting quality end-of-life experiences: the PACE-DLB study.
    Armstrong MJ; Paulson HL; Maixner SM; Fields JA; Lunde AM; Boeve BF; Manning C; Galvin JE; Taylor AS; Li Z
    BMJ Open; 2021 May; 11(5):e047554. PubMed ID: 34039578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholinesterase inhibitors for dementia with Lewy bodies.
    Wild R; Pettit T; Burns A
    Cochrane Database Syst Rev; 2003; 2003(3):CD003672. PubMed ID: 12917981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel.
    Sabbagh MN; Taylor A; Galasko D; Galvin JE; Goldman JG; Leverenz JB; Poston KL; Boeve BF; Irwin DJ; Quinn JF
    Alzheimers Dement (N Y); 2023; 9(1):e12375. PubMed ID: 36873923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics of pathological confirmed prodromal dementia with Lewy bodies.
    Ting SKS; Saffari SE; Hameed S; Chiew HJ; Ng KP; Ng AS
    J Neurol Sci; 2023 Oct; 453():120815. PubMed ID: 37757638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.